Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival

Table 2 Association of quinine oxidoreductase 1 expression with clinical and pathological features of gastric patients

Clinical parameter	NQO1 expression
	High (%)	Low (%)	P value
Age (yr)			0.92
< 60	34 (40.96)	49 (59.04)
≥ 60	37 (40.22)	55 (59.78)
Gender
Male	48 (38.71)	76 (61.29)
Female	23 (45.10)	28 (54.90)
Tumor size (cm)			0.81
< 5	23 (36.51)	40 (63.49)
≥ 5	38 (38.38)	61 (61.62)
Tumor location			0.19
Fundus	18 (40.91)	26 (59.09)
Body	11 (27.50)	29 (72.50)
Antral	34 (41.46)	48 (58.54)
Whole	3 (75.00)	1(25.00)
Tumor staging			0.06
I/II	22 (31.88)	47 (68.12)
III/IV	47 (46.08)	55 (53.92)
Tumor depth			0.37
T1 T2	11 (33.33)	22 (66.67)
T3 T4	58 (41.73)	81 (58.27)
Lymph node metastasis
Yes	12 (27.91)	31 (72.09)
No	54 (43.90)	69 (56.10)
Vascular invasion			0.72
Yes	7 (36.84)	12 (63.16)
No	64 (41.03)	92 (58.97)
Histological differentiation			0.57
Poor	8 (40.00)	12 (60.00)
Moderate	15 (34.10)	29 (65.90)
Well	48 (43.24)	63 (56.76)

According to Table 1, the total case number is 162 based on tumor size, 170 based on tumor location, 171 based on tumor stage, and 172 based on tumor depth.